TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03813160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT02448212
Drug: TS-121
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02448212
Drug: [11C]TASP0410699
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous radiotracer
Study: NCT02205489
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT00155675
Drug: GUSUIBU
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03236324
Drug: Bupivacaine-epinephrine
Normalized name: bupivacaine-epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL bupivacaine 0.25% with epinephrine 2.5 mcg/mL to a maximum of 2.5mg/kg administered on each side as bilateral TFP blocks
Study: NCT02366091
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease
Study: NCT02366091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.
Study: NCT02164084
Drug: Vehicle Gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Gel with hydrogel
Study: NCT02511873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (looks like study drug but has no active ingredients) for 6 weeks with a dose range of 2mg to 8mg daily
Study: NCT03289403
Drug: Immunomodulatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.~Moreover, patients will receive a treatment course of immunomodulatory drugs for 3 -6 months before ICSI cycle:~1. Prednisnlone 40mg for 2 weeks to be lowered gradually till become 5mg after 6 weeks and to be continued~2. Hydroxychloroquine according to body weight, patients who develop hypersensitivity will be shifted to Azathioprin.~3. Immunoglobulins will be used in cases not responding to treatment.
Study: NCT03781128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo in an identical-looking vial as LSD, per os, 3 times within 3 weeks
Study: NCT02925416
Drug: Placebo (D5W)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT03084380
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered at dose of 40mg/kg for 1 day and then fludarabine will be given for the next 5 days and then the T cells will be administered
Study: NCT02825797
Drug: 3BNC117
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 3BNC117
Study: NCT02825797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of placebo (sterile saline)
Study: NCT02872506
Drug: Anti TNF
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are admitted to day hospital with blood test less than 7 days. In the absence of contraindications, hydrocortisone infusion 200 mg will be conducted for 15 minutes followed by anti-TNF treatment infusion over 2 hours for the first three sessions. The following infusions of anti-TNF therapy will be on the same terms without hydrocortisone, every 4 to 8 weeks, in doses of 5-10mg/kg. Adverse effect most frequently reported was URTI. The most serious adverse reactions, were a reactivation of hepatitis B, congestive heart failure, serious infection, serum hypersensitivity reactions, blood diseases, systemic lupus erythematosus / lupus-like syndrome, demyelinating disorders, hepatobiliary metabolism disorders. The QOL will be assessed by IBDQ score at the inclusion visit before the first infusion and at 6 months.
Study: NCT02074891
Drug: coformulated TDF/FTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dose of coformulated TDF/FTC
Study: NCT02727699
Drug: Xanamem™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343
Study: NCT02727699
Drug: Placebo (for Xanamem™)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excipient blend capsules manufactured to mimic Xanamem™ capsules
Study: NCT03734653
Drug: Transdermal Testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be prescribed 2 packets of testosterone gel 1% containing 50mg per packet to apply transdermally daily.
Study: NCT01975129
Drug: Vagitocin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04082533
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will be receiving 100 mg intravenous hydrocortisone every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
Study: NCT00943826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously q2w in the Concurrent and Maintenance Phases and q3w in the Monotherapy Phase.
Study: NCT04189666
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: compare the ability of the drug in preventing postoperative delirium
Study: NCT04090775
Drug: Opdivo Injectable Product
Normalized name: Opdivo Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opdivo (nivolumab): PD-1 inhibitor antibody~Injectable 10mg/mL, only 1 mL injected.
Study: NCT04090775
Drug: Yervoy Injectable Product
Normalized name: Yervoy Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 1 mL injected.
Study: NCT00848666
Drug: Topical therapy
Normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time immersion of the feet in a liquid containing water, alcohol, vinegar, benzoic acid and salicylic acid for a total of 30 minutes.
Study: NCT04034524
Drug: GLP-1 receptor agonist
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: any GLP-1 receptor agonist (other than Saxenda or liraglutide 3.0mg)
Study: NCT00517868
Drug: URG101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder instillation of URG101 or Placebo in random order on treatment 1 and treatment 2 followed by an open-label URG101 on treatment 3 within the same week.
Study: NCT00517868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation without active URG101 drug components
Study: NCT01470352
Drug: Doluxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/d
Study: NCT01470352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: suger pill 30mg/d
Study: NCT02705664
Drug: Loceryl Nail Lacquer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical over entire toenail plates of affected toenails once weekly in the evening (at bed time) after having filled down affected toenails to gently remove as much as affected nails and having cleaned toenails surfaces with the provided cleansing swab
Study: NCT02705664
Drug: Urea Ointment
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical over the infected part of the toenails only once daily under occlusion in the evening (at bed time) after having soaked toenails in warm water and having removed the soften infected toenail plates and dried the toenails
Study: NCT00907179
Drug: LBH 589
Normalized name: CATHETER,EXTERNAL MEDIUM LBH #451-7658
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBH589 three-times-a-week (doses will be at least 2 days apart, e.g. Monday, Wednesday, Friday), until disease progression or intolerable toxicities LBH589 will start the week prior to the first pemetrexed cycle and PD studies will be performed (week -1).~Dose level: 1 LBH589: 10 mg Pemetrexed: 500 mg/m2~Dose level: 2 LBH589: 15 mg Pemetrexed: 500 mg/m2~Dose level: 3 LBH589: 20 mg Pemetrexed: 500 mg/m2~Dose level: 4 LBH589: 30 mg Pemetrexed: 500 mg/m2
Study: NCT00472004
Drug: 17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined, 1 Daily, 1 year duration
Study: NCT00576849
Drug: Balanced HES 130/0.42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume is administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) was \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
Study: NCT00576849
Drug: Balanced HES 130/0.42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
Study: NCT02480946
Drug: MBS2320
Approvals — FDA: no, EMA: no, PMDA: no
Description: As described in the arm descriptions
Study: NCT02480946
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: As described in the arm descriptions
Study: NCT02480946
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Background therapy as described in the arm descriptions
Study: NCT00830895
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD001 10mg/day
Study: NCT01721941
Drug: Phase I Dose level -1
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
Study: NCT01721941
Drug: Phase I dose level 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
Study: NCT01721941
Drug: Phase I Dose level 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
Study: NCT04648033
Drug: Standard of care chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone, cisplatin and vinorelbine are all considered Investigational Medicinal Products (IMPs) in this trial due to the investigation of these drugs in a novel combination. Patients will receive two 21-day cycles of cisplatin and vinorelbine chemotherapy, comprising 80 mg/m2 cisplatin on days 1 \& 22 of their CRT treatment and 15 mg/m2 vinorelbine on days 1, 8, 22 \& 29.
Study: NCT00000549
Drug: progestins
Normalized name: PROGESTINS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00433511
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00433511
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02495038
Drug: 10% reduction of combination of Esmeron® and Nimbex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were randomly assigned to each group by opening of sealed allocation envelope. After collection of data, allocation number was matched with each group. The participants matched at Group S were administered with NMBAs reduced 10% of each ED95. Before patients arrived in the operating room, rocuronium and cisatracurium were prepared by a nurse who was not involved in this study. Each drug dosage was determined by allocation number. The syringe containing each study drug was conveyed to the performer of this study as the status of shielding the scale. The syringes of rocuronium and cisatracurium used each other syringe.
Study: NCT02495038
Drug: 20% reduction of combination of Esmeron® and Nimbex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants matched at Group L were administered with NMBAs reduced 20% of each ED95.
Study: NCT01600625
Drug: oral minocycline hydrochloride treatment
Normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally received 50 mg minocycline (Minocin, SK chemical, Seoul, Korea) twice a day for 2 months treatment
Study: NCT03759301
Drug: Growth Hormones Somatropin Recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormones Somatropin Recombinant 4 IU/day subcutaneous from the 2nd day of the cycle and stopped 1 day before ovum pickup
Study: NCT03759301
Drug: Placebo saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: same volume as growth hormone ampule used
Study: NCT00496600
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
Study: NCT01675089
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The treatment group will receive 15-minute intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
Study: NCT00973011
Drug: FCFD4514S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal escalating dose
Study: NCT00327080
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01550653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02086513
Drug: LDE225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with LDE225
Study: NCT00512057
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01300013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48-hour infusion of placebo
Study: NCT04635800
Drug: MHU650
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHU650 powder for solution for injection
Study: NCT02587117
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each capsule contain 20 mg prednisolone. Each patient was received two capsules of prednisolone (total dose was 40 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
Study: NCT03329014
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control arm
Study: NCT01685398
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03387111
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study: NCT03387111
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study: NCT03387111
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study: NCT03387111
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Study: NCT05279391
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic doses of LMWH (e.g. Tinzaparin 175IU/kg)
Study: NCT01601600
Drug: BYM338
Approvals — FDA: no, EMA: no, PMDA: no
Description: BYM338
Study: NCT01601600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BYM338 Placebo
Study: NCT03140358
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00855270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV saline will be used as placebo for control
Study: NCT00855270
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single dose 90-150mg of Intra Venous Hydrocortisone. 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg.
Study: NCT03846739
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo nasal sprays contain identical ingredients except for the peptide itself.
Study: NCT00093444
Drug: lyso-thermosensitive liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00029159
Drug: androgen
Normalized name: Androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone or placebo capsule, .06mg/kg/day, orally, for 2 years
Study: NCT04518995
Drug: CTP-543 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as tablets.
Study: NCT02732275
Drug: DS-3201b
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-3201 to be administered orally once daily in each 28-day cycle.
Study: NCT01282970
Drug: Placebo to BI 135585
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
Study: NCT00639743
Drug: placebo ( group B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo ( group B)
Study: NCT02732275
Drug: DS-3201b
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-3201 to be administered orally once daily in each 28-day cycle at the recommended dose for expansion.
Study: NCT00281658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel Matching Placebo
Study: NCT02607553
Drug: G-202
Normalized name: krill/om-3/dha/epa/phospho/ast 500 mg-86 mg-25 mg-40 mg-202 mg-101 mcg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle until disease progression
Study: NCT01916863
Drug: LX4211 400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01916863
Drug: LX4211 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02551991
Drug: nal-IRI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02551991
Drug: 5 fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02551991
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03467100
Drug: XEN901
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule filled with XEN901
Study: NCT03467100
Drug: Inert Ingredients Oral Product
Normalized name: inert ingredients Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT00043329
Drug: Actimmune Registry
Approvals — FDA: no, EMA: no, PMDA: no
Description: as administered by physician
Study: NCT03576794
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in both groups will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27.
Study: NCT01884909
Drug: 'TOPROL-XL®' ER Tablets 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 \* 200 mg tablet per day
Study: NCT00120380
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00659347
Drug: DOV 21, 947
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, 25 mg, 2 capsules (1 Active/1 Placebo) BID, 2 weeks Capsules, 25 mg, 2 capsules (2 Active) BID, 2 weeks
Study: NCT00659347
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules,25 mg,BID,6weeks
Study: NCT02236182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04278404
Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Approvals — FDA: no, EMA: no, PMDA: no
Description: The prescribing of drugs to children is not part of this protocol. Participants will receive DOIs as prescribed by their treating provider.
Study: NCT00170898
Drug: Lumiracoxib
Normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01448213
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.
Study: NCT03351205
Drug: estradiol valerate tablets+dydrogesterone tablets
Normalized name: dydrogesterone / estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral estradiol valerate tablets+dydrogesterone tablets
Study: NCT01267968
Drug: GSK2251052
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg (dosing detailed in Arm description)
Study: NCT00680238
Drug: Human derived FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customized for each patient
Study: NCT00419718
Drug: inhaled human insulin
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00791973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 puffs in each nostril once daily for 1 week
Study: NCT01408836
Drug: Intravenous methyl prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methyl prednisolone
Study: NCT01275170
Drug: MK-7655
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg intravenous (IV) over 30 minutes as a single dose
Study: NCT01275170
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine caplet, single 200 mg dose, orally
Study: NCT03372772
Drug: Levocarnitine
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocarnitine syrup- Oral supplementation about 2000mg/ day for 8 weeks